Lori Lawley
Directeur Financier/CFO chez LUMOS PHARMA, INC.
Fortune : 34 536 $ au 30/04/2024
Postes actifs de Lori Lawley
Sociétés | Poste | Début | Fin |
---|---|---|---|
LUMOS PHARMA, INC. | Secrétaire Général | 01/03/2020 | - |
Directeur Financier/CFO | 04/07/2021 | - | |
Comptroller/Controller/Auditor | 01/03/2020 | - |
Historique de carrière de Lori Lawley
Anciens postes connus de Lori Lawley
Sociétés | Poste | Début | Fin |
---|---|---|---|
LUMOS PHARMA, INC. | Comptroller/Controller/Auditor | 26/07/2018 | 01/03/2020 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/10/2014 | 01/04/2015 |
Formation de Lori Lawley
McCombs School of Business | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Emirats Arabes Unis | 2 |
2 |
Opérationnelle
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Corporate Secretary | 1 |
Sectorielle
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
LUMOS PHARMA, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
NewLink Genetics Corp.
NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
- Bourse
- Insiders
- Lori Lawley
- Expérience